目錄:MedChemExpress LLC>>生化試劑>> Lurbinectedin | MCE
CAS | 497871-47-3 | 純度 | 99.80% |
---|---|---|---|
分子量 | 784.87 | 分子式 | C??H??N?O??S |
供貨周期 | 現貨 | 規格 | 1 mg |
貨號 | HY-16293 | 應用領域 | 醫療衛生,化工,生物產業,制藥 |
MCE 的所有產品僅用作科學研究或藥證申報,我們不為任何個人用途提供產品和服務。
CAS No. : 497871-47-3
產品活性:Lurbinectedin (PM01183) is a DNA minor groove covalent binder with potent anti-tumour activity; inhibits RMG1 and RMG2 cell growth with IC50 values of 1.25 and 1.16 nM, respectively.
研究領域:Cell Cycle/DNA Damage
作用靶點:DNA Alkylator/Crosslinker | DNA/RNA Synthesis
In Vitro: PM01183 is a new synthetic tetrahydroisoquinoline alkaloid that is currently in phase I clinical development for the treatment of solid tumours. PM01183–DNA adducts in living cells give rise to double-strand breaks, triggering S-phase accumulation and apoptosis. The potent cytotoxic activity of PM01183 is ascertained in a 23-cell line panel with a mean GI50 value of 2.7 nM. Lurbinectedin exhibits significant antitumor activity toward chemosensitive and chemoresistant human ovarian clear cell carcinoma (CCC) cells in vitro.
In Vivo: Mouse CCC cell xenografts reveals that lurbinectedin significantly inhibits tumor growth. Lurbinectedin plus SN-38 results in a significant synergistic effect. In four murine xenograft models of human cancer, PM01183 inhibits tumour growth significantly with no weight loss of treated animals. Single lurbinectedin or NSC 119875-combined therapies are effective in treating NSC 119875-sensitive and NSC 119875-resistant preclinical ovarian tumor models. The strongest synergistic effect is observed for combined treatments, especially in NSC 119875-resistant tumors. Lurbinectedin tumor growth inhibition is associated with reduced proliferation, increased rate of aberrant mitosis, and subsequent induced apoptosis.
相關產品:Drug Repurposing Compound Library Plus | FDA-Approved Drug Library Plus | Bioactive Compound Library Plus | IBU-DC Phosphoramidite | 2,4-D sodium salt | Thailanstatin D | Busulfan | Carboplatin-d4 | Caracemide | Farudodstat | DNA31 | 2'-OMe-Ac-C Phosphoramidite | Dasabuvir | DNA Gyrase-IN-4 | Uridine triphosphate-13C9,15N2 (sodium) | 5-Methylcytosine | Cidofovir dihydrate | Capecitabine-d11 | Tezacitabine | Mequindox | (+)-CBI-CDPI1 | 2-Iodoacetamide | 5-Methylcytosine-d4 | Duocarmycin GA | TH287 hydrochloride | DNA Gyrase-IN-1 | 2'-O-MOE-5-Me-rU | Palifosfamide tromethamine | Levofloxacin sodium | GC7 Sulfate | Mipicoledine | Psammaplin A | hDHODH-IN-2
熱門產品線:重組蛋白 | 化合物庫 | 天然產物 | 熒光染料 | PROTAC | 同位素標記物 | 寡核苷酸 | 抗體 | 點擊化學
Trending products:Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Fluorescent Dye | PROTAC | Isotope-Labeled Compounds | Oligonucleotides | Antibodies | Click Chemistry
品牌介紹:
• MCE (MedChemExpress) 擁有200 多種全球僅有化合物庫,我們致力于為全球科研客戶提供前沿的高品質小分子活性化合物;
• 50,000 多種高選擇性抑制劑、激動劑涉及各熱門信號通路及疾病領;
• 產品種類涵蓋各種重組蛋白,多肽,常用試劑盒 ,更有 PROTAC、ADC 等特色產品,廣泛應用于新藥研發、生命科學等科研項目;
• 提供虛擬篩選,離子通道篩選,代謝組學分析檢測分析,藥物篩選等專業技術服務;
• 設有專業的實驗中心和嚴格的質控、驗證體系;
• 提供 LC/MS、NMR、HPLC、手性分析、元素分析等各項質檢報告,確保產品的高純度、高品質;
• 產品的生物活性多經各國客戶實驗驗證;
• Nature, Cell, Science 等多種頂級期刊及制藥 Patent 收錄了MCE客戶的科研成果;
• 專業團隊跟蹤最新的制藥及生命科學研究進展,為您提供全球新的活性化合物;
• 與世界各大制藥公司及著名科研機構建立了長期的合作。